Cogent Biosciences Inc Stock Price, News & Analysis

Cogent Biosciences (NASDAQ: COGT) reported significant achievements in Q2 2025, highlighted by positive top-line results from the SUMMIT trial evaluating bezuclastinib in NonAdvanced Systemic Mastocytosis. The trial met its primary endpoint with a statistically significant improvement in Total Symptom Score (24.3-point reduction vs. 15.4 points for placebo, p=0.0002).

The company strengthened its financial position through two major transactions: a $400 million debt facility with SLR Capital Partners and an upsized $230 million public offering. With $453 million in pro-forma cash, Cogent is funded through anticipated launch and into 2027. Q2 2025 resulted in a net loss of $73.5 million, with R&D expenses of $62.2 million.

Key upcoming catalysts include pivotal trial results from PEAK (GIST) and APEX (AdvSM) trials in 2H 2025, followed by the company's first NDA submission by year-end.

Cogent Biosciences (NASDAQ: COGT) has successfully closed its upsized public offering of 25,555,556 shares of common stock at $9.00 per share, including the full exercise of underwriters' option to purchase additional shares. The offering generated approximately $230 million in gross proceeds before deducting expenses.

The biotechnology company, focused on precision therapies for genetically defined diseases, plans to use the proceeds for development and commercial preparation of bezuclastinib and other product candidates. J.P. Morgan, Leerink Partners, and Guggenheim Securities served as joint book-running managers, with LifeSci Capital acting as lead manager.

Cogent Biosciences (NASDAQ: COGT) has announced the pricing of its upsized public offering of 22,222,223 shares of common stock at $9.00 per share, expecting to raise approximately $200 million in gross proceeds.

The offering includes a 30-day option for underwriters to purchase up to an additional 3,333,333 shares under the same terms. The company plans to use the proceeds for bezuclastinib development, regulatory and commercial preparation activities, and general corporate purposes. The offering is expected to close around July 10, 2025.

J.P. Morgan, Leerink Partners, and Guggenheim Securities are serving as joint book-running managers, with LifeSci Capital acting as lead manager for the offering.

Cogent Biosciences (NASDAQ: COGT), a biotechnology company specializing in precision therapies, has announced a proposed $150 million public offering of common stock. The company will also grant underwriters a 30-day option to purchase up to an additional $22.5 million of shares.

The proceeds will fund the development and commercial preparation of bezuclastinib and other product candidates, support bezuclastinib's planned commercial launch, and provide working capital. J.P. Morgan, Leerink Partners, and Guggenheim Securities are serving as joint book-running managers, with LifeSci Capital as lead manager.

Cogent Biosciences (NASDAQ: COGT) announced breakthrough results from its SUMMIT trial evaluating bezuclastinib in non-advanced systemic mastocytosis patients. The drug achieved statistical significance across all primary and secondary endpoints, demonstrating a superior mean change in total symptom score of -24.3 points versus -15.4 for placebo (p=0.0002).

Key highlights include 87.4% of treated patients achieving ≥50% reduction in serum tryptase compared to 0% for placebo. The drug showed a favorable safety profile with mostly low-grade adverse events. The company plans to submit an NDA to FDA by end of 2025, supported by a strong financial position of $237 million cash and access to $350 million in debt facility.

Additionally, Cogent expects to share results from pivotal trials PEAK (GIST) and APEX (AdvSM) in 2H 2025.

Cogent Biosciences (NASDAQ: COGT) has secured a $400 million non-dilutive debt financing facility from SLR Capital Partners, strengthening its financial position ahead of key clinical milestones. The company drew an initial $50 million at closing, with additional tranches available based on clinical and commercial achievements. The financing supports bezuclastinib's expected 2026 launch and upcoming pivotal trial results. Cogent anticipates three major trial readouts in 2025: SUMMIT results in July (NonAdvSM), APEX results in H2 (AdvSM), and PEAK results (imatinib-resistant GIST) by year-end. The facility includes $100 million available upon successful SUMMIT and PEAK data readouts, $50 million tied to early commercial success, and $200 million by mutual agreement.

Cogent Biosciences (NASDAQ: COGT), a biotechnology company specializing in precision therapies for genetically defined diseases, has announced its upcoming presentation at the Jefferies Global Healthcare Conference on June 5, 2025, at 7:35 a.m. ET. The presentation will be accessible via webcast on the company's investor relations website, with a replay available for 30 days.

Additionally, the company disclosed the approval of inducement equity awards for five new employees under its 2020 Inducement Plan. The awards consist of options to purchase 127,000 shares of Cogent common stock, featuring a 10-year term and a four-year vesting schedule.

Cogent Biosciences (NASDAQ: COGT) reported Q1 2025 financial results and provided key business updates. The company is preparing for three major clinical trial readouts in 2025: SUMMIT trial results for nonadvanced systemic mastocytosis in July, APEX trial for advanced systemic mastocytosis in H2, and PEAK trial for GIST by year-end. Recent highlights include positive clinical data from SUMMIT's Open Label Extension, showing 65% mean improvement in Total Symptom Score at 48 weeks. Financially, Cogent ended Q1 with $245.7 million in cash, expected to fund operations into late 2026. The company reported increased R&D expenses of $63.0 million (vs $52.7M in Q1 2024) and a net loss of $72.0 million (vs $58.3M in Q1 2024). The company raised $24.3 million through ATM stock offering during the quarter.

Cogent Biosciences (Nasdaq: COGT) presented preclinical data from four pipeline programs at the AACR 2025 Annual Meeting in Chicago. The presentations included: a pan KRAS(ON) inhibitor showing 90% tumor growth inhibition; CGT6297, a PI3Kα inhibitor targeting H1047R and helical mutations; CGT4859, a selective FGFR2/3 inhibitor currently in Phase 1 trials; and CGT4255, a brain-penetrant ErbB2 inhibitor.

The company also announced two key leadership appointments: Ray Frost as SVP of Market Access and Dr. Adam Boyd as SVP of Corporate Strategy. Additionally, Cogent granted inducement equity awards to five new employees, including nonqualified options to purchase 446,000 shares with a 4-year vesting schedule.